Wednesday, March 15, 2017

US FDA News: Viberzi (eluxadoline): Drug Safety Communication - Increased Risk of Serious Pancreatitis In Patients Without A Gallbladder

Patients who do not have a gallbladder should not take Viberzi. Developing pancreatitis could result in hospitalization or death.
Read more: Viberzi (eluxadoline): Drug Safety Communication - Increased Risk of Serious Pancreatitis In Patients Without A Gallbladder